This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.

Science Hub

Welcome to Novo Nordisk Science Hub

The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.


This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.

Are you a healthcare professional?

University of Glasgow, Glasgow, United Kingdom

Mark Petrie is Professor of Cardiology at the University of Glasgow, Glasgow, UK. In Glasgow Royal Infirmary he runs a broad-ranging heart failure service alongside nurses and pharmacists. He also is a member of the Scottish National Advanced Heart Failure team at the Golden Jubilee National Hospital, Clydebank, UK, which he directed until 2014. 

He is in leadership positions of many trials, including STICH, REVIVED, EMPACT-MI, STEP-HF, REDUCE-LAP, Dapa-HF, PARADISE-MI, RELIEHF-HF, FINEARTS, and IRONMAN. Professor Petrie has published over 200 manuscripts, including many in journals such as the New England Journal of Medicine, The Lancet, Circulation, JACC and the European Heart Journal.


His clinical and research interests in diabetes and heart failure began in 2006.  He was a senior author of the 2018 European Society of Cardiology (ESC) heart failure and diabetes consensus statement, an author of the ESC NSTEMI Guidelines and a reviewer of the 2016 ESC HF Guidelines. Prof. Petrie has chaired or been a member of the clinical events committees of EMPA REG-OUTCOME, CARMELINA, CAROLINA, DELIVER as well as around 30 other trials.  


Matthew Cavender

University of North Carolina, Chapel Hill, USA

Dr. Matthew A. Cavender, MD, MPH is an Assistant Professor and the Director of the Cardiology Clinical Outcomes Group and Co-Director of Cardiovascular Clinical Trials at the University of North Carolina in Chapel Hill, NC.


He received his medical degree from the University of Alabama School of Medicine and a Master’s of Public Health from the Harvard School of Public Health. He completed an internship and residency in Internal Medicine at Duke University in Durham, North Carolina, clinical fellowship in cardiology at the Cleveland Clinic in Cleveland, Ohio, and a research and interventional cardiology fellowship at Brigham and Women’s Hospital in Boston, Massachusetts.


He is clinically active as an interventional cardiologist and specializes in transcatheter therapies for patients with advanced coronary artery disease, peripheral vascular disease and valvular heart disease. He has extensive experience in clinical research studying the clinical effectiveness of clinical interventions, devices, and pharmacotherapies.  His research efforts are focused on the effectiveness of existing treatment strategies and therapies for patients with cardiovascular disease, the impact of diabetes on cardiovascular events among patients with coronary artery disease, and pharmacologic and interventional strategies to improve outcomes in patients with diabetes and atherosclerosis.


Dr. Cavender is a Fellow of the American College of Cardiology and member of a number of medical societies and organizations, including the American Heart Association Council of Clinical Cardiology, and the Society for Cardiovascular Angiography and Interventions. Dr. Cavender has authored numerous works on pharmacologic and interventional therapies for patients with coronary artery disease, valvular heart disease, diabetes, and myocardial infarction that have been published in peer-reviewed journals including The New England Journal of Medicine, The Lancet, Circulation and The Journal of the American College of Cardiology. He is on the editorial board of Circulation: Cardiovascular Interventions, Clinical Cardiology, and the American Heart Journal.

Read full bio